Serum neurofilament light chain levels as biomarker of paclitaxel-induced cognitive impairment in patients with breast cancer: a prospective study

Objective To prospectively assess the utility of serum neurofilament light chain (sNfL) levels in identifying the risk to develop chemotherapy-induced cognitive impairment (CICI) in cancer patients. We also examined if sNfL can be identified as an early biomarker of CICI development. Methods We long...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Supportive care in cancer Jg. 30; H. 2; S. 1807 - 1814
Hauptverfasser: Argyriou, Andreas A., Karteri, Sofia, Bruna, Jordi, Mariotto, Sara, Simo, Marta, Velissaris, Dimitrios, Kalofonou, Foteini, Cavaletti, Guido, Ferrari, Sergio, Kalofonos, Haralabos P.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Berlin/Heidelberg Springer Berlin Heidelberg 01.02.2022
Springer
Springer Nature B.V
Schlagworte:
Aged
Antimitotic agents
Antineoplastic agents
Biological markers
Biomarkers
Breast cancer
Breast Neoplasms - drug therapy
Cancer
Cancer patients
Care and treatment
Chemotherapy
Clinical significance
Cognition
Cognitive ability
Cognitive Dysfunction - chemically induced
Cognitive Dysfunction - diagnosis
Cognitive impairment
Complications and side effects
Critical incidents
Female
Health aspects
Humans
Intermediate Filaments
Longitudinal studies
Medical treatment
Medicine
Medicine & Public Health
Middle Aged
Multiple Sclerosis
Nursing
Nursing Research
Oncology
Oncology, Experimental
Original Article
Paclitaxel - adverse effects
Pain Medicine
Palliative care
Patients
Prospective Studies
Rehabilitation Medicine
Serum
Women
Biomarker
Chemotherapy-induced cognitive impairment
Serum neurofilament light chain
Prediction
ISSN:0941-4355, 1433-7339, 1433-7339
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective To prospectively assess the utility of serum neurofilament light chain (sNfL) levels in identifying the risk to develop chemotherapy-induced cognitive impairment (CICI) in cancer patients. We also examined if sNfL can be identified as an early biomarker of CICI development. Methods We longitudinally measured sNfL levels in 20 female patients with breast cancer, scheduled to receive the 12 weekly paclitaxel-based regimen. An equal number of age-matched female heathy subjects was incuded as control group. CICI was graded by means of the Montreal Cognitive Assessment scale (MOCA); peripheral neurotoxicity (PN) was graded using the neurosensory Common Criteria for Adverse Events (CTCAE)v5.0, while sNfL levels were quantified using a high-sensitive technique (Quanterix, Simoa) before the administration of chemotherapy (T0), after 3 courses (T1), and at the end of chemotherapy (T2). Results Pre-treatment sNfL levels were comparable in patients and controls ( p  = 0.103). At T2, 5/20 patients (mean age 61.4 ± 5.0 years) developed CICI. These 5 patients also had clinically-significant PN. Patients with and without CICI had comparable sNfL values at T2 ( p  = 0.1). In addition, at T2, sNfL levels did not correlate significantly with MOCA score in CICI patients ( p  = 0.604). The difference of sNfL levels between T1 and T0 failed to predict independently the occurrence of CICI at T2. Conclusion Our findings do not support the utility of measuring sNfL levels as a biomarker of CICI. Grade 2–3 PN most strongly confounded our outcomes. Considering the small sample size, which might have prevented the results from being extrapolated, further testing in larger studies is warranted.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0941-4355
1433-7339
1433-7339
DOI:10.1007/s00520-021-06509-x